Highly Motivated Expert Partners for Trial Conduct

- **13** Partnership with Precision Medicine Diagnostic Companies and Leading Pharmaceutical Companies
- **13** Investigational Drugs or Drug Combinations Tested
- **16 Initiated | 14 Completed** Sub-Studies Conducted
- **10** Agents Against Specific Tumor Mutations/Genetic Signatures Tested in NSCLC
- **12** Month Average Sub-Study Stand Up Time from Approval by the Lung-MAP Drug Selection Committee to Activation
- **22** Month Average Time to Target Accrual Completion for ~80 Person Study, Driven by Biomarker Prevalence
- **~4,000 | ~650 Per Year** Patients Screened
- **~2,500** Patients Eligible for a Treatment in a Well-Designed Trial
- **~1,000 | 150+ Per Year** Patients Treated with Cutting-Edge Therapies
- **300+** Altered Genes Interrogated in Each Patient’s Tumor
- **24%** Underserved Minority Participants Enrolled
- **8** Organizations, Including NCI and FDA, Working Together to Conduct and Oversee the Study
- **10,000+** Annotated Specimens in a Tissue Bank to Allow Deeper Scientific Studies to Influence Future Trials
- **30+** Publications and Abstracts

**Additional Benefits of Lung-MAP**
- Shared Costs and Risks of Testing Therapeutics for Companies
- Fostering Drug Combination Collaborations Between Companies
- Accelerated Timeframes for Evaluation of Treatment Efficacy Due to the Large Network
- Strong Support from the FDA with Ability for Studies to Have Regulatory Intent

**Nearly 30 Public and Private Collaborators and Supporters in Partnership since 2014**

- **FNIH**
- **Friends of Cancer Research**
- **NCI National Clinical Trials Network**
- **SWOG Cancer Research Group**
- **ECOG-ACRIN Cancer Research Group**
- **NRG Oncology**
- **Alliance**

**A Master Protocol to Evaluate Biomarker-Driven and Immune Therapies in Previously Treated Non-Small Cell Lung Cancer**

900+ Trial Sites with Physicians and Researchers from Cutting-Edge Academic and Community Treatment Centers

~50% Accrual from Community Based Sites